Summary

Eligibility
for people ages 18 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Urmimala Sarkar, MD, MPH (ucsf)Ma Somsouk, MD, MAS (ucsf)
Headshot of Urmimala Sarkar
Urmimala Sarkar

Description

Summary

Complete and timely colonoscopy after an abnormal stool-based colorectal cancer screening test results in early detection, cancer prevention, and reduction in mortality, but follow-up in safety-net health systems occurs in less than 50% at 6 months. The proposal will implement multi-level approach consisting of a stepped-wedge clinic-level intervention of team-based best practices co-developed with primary and specialty care, a patient-level technology intervention to provide enhanced instructions and navigation to complete diagnostic colonoscopy, and a mixed methods evaluation to explore multi-level factors contributing to intervention outcomes. Developing a solution to this high-risk and diverse population has the potential to translate to other health systems, support patient self-management, and address other patient conditions.

Details

Keywords

Colon Cancer, Cancer Colorectal, Colorectal Cancer, Colorectal Neoplasms, Colonic Neoplasms, BPB, No PIN, BPB, PIN, No BPB, PIN, No BPB, No PIN

Eligibility

Location

  • Zuckerberg San Francisco General Hospital accepting new patients
    San Francisco California 94110 United States

Lead Scientists at University of California Health

  • Urmimala Sarkar, MD, MPH (ucsf)
    Urmimala Sarkar MD, MPH is Professor of Medicine at UCSF in the Division of General Internal Medicine, Associate Chair for Faculty Experience for the Department of Medicine, Associate Director of the UCSF Center for Vulnerable Populations, and a primary care physician at Zuckerberg San Francisco General Hospital’s Richard H. Fine People's Clinic.
  • Ma Somsouk, MD, MAS (ucsf)
    1. Programmatic implementation of population-based colorectal cancer screening and follow-up of abnormal screening results. We embrace big data and technology to design, develop, and deliver economic and effective services for patients and health systems. 2. Use of human gut samples to study HIV, Covid-19, barrier function, systemic inflammation, inflammatory bowel disease, and microbiome.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT06191185
Study Type
Interventional
Participants
Expecting 2000 study participants
Last Updated